T oxoplasma take up residence in vacuoles that exdude host membrane glycoproteins. Such vacuoles fail to fuse with acidifying lysosomes and endosomes thus protecting the parasites from lethaI host responses. However, jf the tachyzoites are coated with antibody, they are bound by macrophage Fc receptors (FcR); the blocks in fusion and acidification of the vacuoles are overcome and the microbes are killed by triggering the macrophage's respiratory burst. The mechanism of this FcRmediated reversal of the block in fusion and acidification is not yet dear but studies using respiratoryburst-negative ceIls transfected with various FcR mutants have shown that distinct domains of the cytoplasmic tail of the FcR direct endocytosis and phagocytosis.
Leishmania adopt a different entry and survival strategy. They passively attach to various receptors, including complement receptors, on the host cell surface by means of lipophosphoglycan and gp63 and are taken up by conventional phagocytosis. Leishmania-conraining phagosomes fuse effectively with lysosomes, as shown by the presence of lysosomal enzymes within the parasitophorous vacuole (D. RusselI; St Louis) and kinetic studies have revealed that a constant supply of lysosomal enzymes is likely to be released into these vacuoles. The The macrophage as an APC plays a key role in determining whether or not a cellular immune response promotes protection of the host or survival of the infectious agent. One important factor is the level of expression of MHC molecuJes; as an illustration of this, H-D. Volk (Berlin) showed data demonstrating that in patients with septicemia there is a dose association between reduction in monocyte HLA-DR expression and fatal outcome.
Researchers interested in immunologi-
MHC antigen expression is modulated by T-cell-derived cytokines but can also be profoundly influenced by the natural resistance gene Beg (which is probably identical to lty and Lsh). Beg is located on mouse chromosome 1 and, presumably, on human chromosome 2q, within a set of genes coding for cytoskeletal proteins (E. Skarnene, Montreal). In its two allelic forms Beg confers resistance and susceptibility to infeetion with Salmonella typhimurium, Leishmania donovani, mycobacteria and other macrophagic parasites in mice and preliminary studies in humans suggest a similar dichotomy. The Beg gene product, in addition to controlling MHC dass 11 antigen expression, affects 5' nudeotidase activation, the respiratory burst and expression of the ligand for AcM.l, an antibody that recognizes activated macrophagcs.
MHC molecules direct the immune system towards responses media ted largely by either CD4 + or CD8+ T cells and this may be partly controlled by the site of intersection of MHC molecules and peptide. Thus infected macrophages may present a distinct set of peptides, and induce a response of different emphasis to that induced by uninfected macrophages that acquire locallyavailable peptides by endocytosis.
The suggestion by J. Louis (Lausanne) that live and dead parasites induce different T -cell subsets is in agreement with this possibility. The divergent responses induced may be synergistic: in cutaneous leishmaniasis, resistance to disease is induced by CD4 + cells without the requirement for CD8+ cells. However, CD8+ cells enhance the development of resistance by their ability to produce gamma-interferon (IFN--y) (Louis) and an optimal balance between the two subsets may be required for maximal protection, as was found by M.A. Mielke (Berlin) for listeriosis and brucellosis.
A different way of stimulating T cells is used by staphylococcal enterotoxins (SE). The mitogenic T -cell response induced by these and other 'superantigens' is dependent on MHC dass II molecules present on APCs but is not MHC-restricted and does not require processing. Different SEs lead to the preferential expansion of T cells expressing a particular V wencoded gene segment of the T-cell receptor (TCR). Ir has been suggested that the SE, TCR and MHC dass II molecules form a trimolecular complex with bivalent SE crosslinking variable parts of the TCR and conserved regions of MHC moleeules (B. Fleischer, Mainz; C. Janeway, New Haven). An alternative model for SE action was proposed by C. Janeway: SE may alter a putative endogenous co-Iigand in a way that it crosslinks V ß of the TCR and MHC molecules sufficiently to activate a T cell. The endogenous equivalents of superantigens in mice, the products of the Mis locu5, may be anormal constituent of cellinteractions.
The complex mechanisms governing processing, presentation and recognition make the question oi what characterizes a T -cell antigen difficult to answer. Several studies have suggested that T-cell antigens need not necessarily be proteins. For example, in mice, lipophosphoglyean from L. major induees protection that can be transferred by CD4 + T cells (H. Moll, Erlangen) and human T eells bearing the rS-T-cdl receptor can respond to mycobacterial components that are resistant to protease digestion (K. Pfeffer, Munieh).
Macrophages as anri-microbial effector cells
To destroy invading organisms macrophages need to convert from a state that sustains intracellular replication of microbes to an activated state. C. Nathan (New York) summarized reeent progress in the understanding of thc proccsses regulating macrophage activation, particularly the biochemical pathways that may be used to generate toxie reactive oxygen and nitrogen intermediates (ROI; RN!). RNI can be regarded as sequential intermediates in the oxidation of a guanidonitrogen trom L-arginine to nitrate. The microbial target molecules for RN! have yet to be identified but it seems likely that they will be found in metabolie pathways such as e1ec-tron transport chains, the tricarboxylic acid cyde and DNA synthesis.
The list of cytokines acring on macrophages to induce ROI and RNI and otherwise enhancing anti-microbial activity is long and indudes granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumour necrosis facror-a (TNF-a). These powerful mediators must be carefully controlIed: e1ev-ated and sustained production of TNF-a correlates with the severity of a number of infectious diseases, including shock in bacterial sepsis, although TNF-a seems to have a beneficial role when produced 10-cally and transiently. V. Kindler (Geneva), for example, showed in ex vivo studies that, in mice infected with BCG, TNF-ct is synthesized 10-eally at the site of inflammation and is essential for granuloma formation and antibacterial macrophage activation. M-L. Lohmann-Matthes (Hannover) reported that TNF-ct acts not only in soluble form but also, and perhaps more importantly to 10cal activity, as a membraneassociated molecule.
Dealing with a single cytokine on an isolated population of reHs may be a gross oversimplification of events in viva, as essenrially
Immunology Today 5 Vol.12, No. 1 1991 all macrophage-activating cytokines are produced at low concentrations during an ongoing infection. W. Solbach (Erlangen) showed that TNF-ct and interleukin 4 (IL-4) in low concentrations independently synergize with IFN--y for macrophage activation whereas none of these cytokines was very effective as a single agent. The cell activation induced by the combination of ILA and IFN-"{ could be blocked compietely using antibodies to TNF-ct and Sol bach, therefore, proposed that ILA combined with IFN--y induces the production of TNF-a by macrophages; TNF-a then synergizes with IFN-"{ to activate the cells for anti-parasite activity.
Since the results of macrophage acrivation are potentially detrimental to the host, it is not surprising that soluble factors that deactivate macrophages have been discovered. Exciting work from Nathan's group has attributed this activity to macrophage-deactivating factor (MDF) and transforming growth factor ~ (TGF-ß). MDF, a 13 kDa protein, has been purified to homogeneity and apparently interferes wirh ROI production by reducing the affinity of the enzyme NADPH:0 2 oxidoreductase for the co-substrate NADPH. MDF is distinet from TGF-ß since neither the antibodies nor the cell surface receptors that bind TGF-ß recognize MDF.
Vaccination and treatment
Several speakers discussed the implications of recent findings for vaccination prophylaxis and treatment of infections. A. Sher (Bethesda) reca lied that live attenuated vaccines usually induce a better level of proteetion than purified or recombinant immunogens. This was also testified to by R. Pink (Basel), K. Früh (Heidelberg) and B. Knapp (Marburg}, all of whom work on molecularly-defined immunogens from Plasmodium falciparum.
Major differences between living and non-living vaccines are antigen persistence in the vaccinee and the inability, so far, to target non-living immunogens to macrophages in a form that induees a protective immune response.
Protective immune responses can be mediated by either CD4+ or Plasmodium chabaudi that, in addition to IFN-'Y, CD4+ T-celldependent antibody production was essential for complete clearance of the pathogen. Conversely, the presence of high levels of IFN-'Y does not necessarily indicate protection (Louis). Vaccination against Lyme disease using the outer surface protein A (OspA) of Borre/ia burgdor-(eri in duces a protective antibody response in mice (M. Simon, Freiburg) and the same antigen stimulates T cells from patients with Lyme arthritis (G. Burmester, Erlangen). Clearly the type of immune response that gives optimal protection varies with the pathogen. For this reason a great deal more information on basic immunesystem-parasite interaction is required before optimized vaccine protocols can be developed.
In addition to active immunization, passive immunoenhancing therapy deserves attention in the future. This approach has proved to be effective in trials of IFN-'Y and GM-CSF. G. Kaplan (New York) is now assessing intradermal deposition of IL-2 into lesions of patients with lepromatous leprosy. Another strategy of intervention is the blockade of stimuli inducing detrimental TNF responses, as was successfully performed in patients with Gramnegative sepsis that were given antibodies to lipopolysaccharide (LPS) (B. Baumgartner, Lausanne). A third strategy, that of blocking macrophage deactivation, will be used in the near future.
Clearly vaccine development is an area of great interest and of considerable, if as yet unfulfilled, potential. The increasing awareness of host-parasite interactions will surely supply the momentum for further advancement in the near future. 
Werner Solbach, Heidrun Moll and

Today's ImmunoJogy Today
In this issue, the first of 1991, we launch a new look for Immunology Today. The aim of the redesign is first and foremost to make the journal more accessible to readers by simplifying the layout, improving the readability of the text and enhancing its appearance. To achieve this we have altered the section names, typeface and logo and introduced a centered page layout and an elegant, dear typeface that is easy on the eye.
One of the most noticeable and appealing changes is to the Contents page, which can now be found on page 3. The previous 'busy' arrangement has been replaced by a much dearer, more functional design. Section titles have also been altered.
Trends, which replaces News and Features, will focus on new directions in immunological research with a combination of short, themed meeting reports and other major news stories. Another purpose of the redesign is to distinguish more dearly between speculative artides and review papers. With this in mind, and to reflect its content more accurately, the Rostrum section has been renamed Viewpoint. In every other respect it is unchanged: it will continue to be the forum for airing new hypotheses, debating controversial topics and exploring the leading edges of immunology. Most of the articles will, as always, be suggested by readers.
Concise, readable and informative reviews commissioned from leading researchers will remain at the heart of each issue. The timeliness and high quality of these articles have helped to make Immunology Today the most popular way for immunologists to stay up to date with this exciting and fast-moving subject.
Editorial pages have been increased to 580 for 1991 and to make the most of this windfall for readers an entirely new section, Kaleidoscope, has been introduced. As the name suggests, Kaleidoscope will contain a rieh variety of new artieies that will extend the scope of the journal. For example, in this issue the first of an occasional history © 1991. Elsevier Seiene. Publishe" LId. UK. 0167--4919/91/$02.00
Immunology Today 6 Vol. 12, No. 1 1991 series, Immunology Yesterday, is featured. Future topics will include articles on national and international immunology organizations, a 'Good Journal Guide', book review supplements, guidelines for science writing and design of figures and insights into the application of immunology in industry. An expanded correspondence section, book reviews and the meetings diary will be regular components of
Kaleidoscope.
We would like to extend our thanks and congratulations to Sheila Betts (Graphie Design) who is responsible for the new look and to gratefully acknowledge the input of the Production Department of Elsevier Trends Journals, particularly Judith Basrin, and of Susan Gatell, Marketing Manager.
Comments on the content and suggestions for further improvements to the design will always be welcomed.
Richard B. Gallagher
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